DYN | Jotup

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

Retrieved on:

Wednesday, March 27, 2024

Employment, Therapy, DYN, Compensated emancipation, Pharmaceutical industry

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points:

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
(Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox.
The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox’s acceptance of employment with Dyne under Dyne’s 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity award is subject to the terms and conditions of the award agreement covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

Retrieved on:

Wednesday, March 27, 2024

DYN, Therapy, MPH

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points:

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
(Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024 at 9:50 a.m.
ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

Dyne Therapeutics Announces CEO Transition

Retrieved on:

Monday, March 25, 2024

Arizona State University, California State University, Cell biology, Research, University, DM1, Dynamos, Biology, MBA, Biogen, Bioverativ, Therapy, DYN, DMD, Management

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.

Key Points:

- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
Mr. Brumm will serve as an advisor to Dyne to help ensure a seamless transition.
Having worked extensively in rare diseases, I appreciate the meaningful impact that novel therapeutics can have on a patient community,” said Mr. Cox.
Most recently, he served as CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022.

Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days

Retrieved on:

Wednesday, March 13, 2024

DYN, Therapy

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.

Key Points:

WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m.
ET.
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation.

Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on:

Tuesday, March 5, 2024

WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.

Key Points:

(Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2023 and recent business highlights.
Net loss: Net loss for the quarter ended December 31, 2023 was $66.6 million, or $1.09 per basic and diluted share.
This compares with a net loss of $38.8 million, or $0.74 per basic and diluted share, for the quarter ended December 31, 2022.
Net loss for the year ended December 31, 2023 was $235.9 million, or $3.95 per basic and diluted share.

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Retrieved on:

Wednesday, February 14, 2024

Therapy, Nationwide, Principal, DYN, DMD, Duchenne muscular dystrophy, Conference, DM1, Gene therapy, Safety, Muscular Dystrophy Association, Patient, MPH, Asian literature, PMO, Myopathy, MDA, Episcopal conference, Pharmaceutical industry

WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced two oral presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida and virtually.

Key Points:

Both presentations will highlight the initial clinical data from the ACHIEVE and DELIVER trials reported by Dyne in January 2024.
The initial clinical data from the ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) includes 6-month data from the 1.8 mg/kg (approximate ASO dose) cohort (n=16) and 3-month data from the 3.4 mg/kg Q4W cohort (n=16).
Initial 6-month clinical data from the 5 mg/kg (approximate PMO dose) cohort (n=6) of the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping will also be presented.
Additionally, both presentations will include safety data from multiple cohorts in ACHIEVE and DELIVER trials which was shared in January.

Dyne Therapeutics to Present at February Investor Conferences

Retrieved on:

Thursday, February 1, 2024

Therapy, DYN, Conference, Pharmaceutical industry

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .

Key Points:

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc .
(Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in February:
Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference, fireside chat on Thursday, February 8, 2024 at 11:00 a.m.
ET in New York
Oppenheimer 34th Annual Healthcare Life Sciences Conference, virtual fireside chat on Wednesday, February 14, 2024 at 2:40 p.m.
ET
A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on:

Thursday, January 11, 2024

The gross proceeds to Dyne from the offering were approximately $345.1 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne.

Key Points:

The gross proceeds to Dyne from the offering were approximately $345.1 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne.
All of the shares in the offering were sold by Dyne.
Morgan Stanley, J.P. Morgan, Jefferies and Stifel acted as joint book-running managers for the offering.
The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statements.

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on:

Friday, January 5, 2024

Conference, Therapy, DYN

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m.

Key Points:

WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 2:15 p.m. PT (5:15 p.m.
ET).
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

Retrieved on:

Friday, January 5, 2024

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share.

Key Points:

WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 17,150,000 shares of its common stock at a public offering price of $17.50 per share.
The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be approximately $300.1 million.
All shares in the offering are being sold by Dyne.
In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,572,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions.